Ventyx Biosciences Analyst Ratings
Oppenheimer Maintains Outperform on Ventyx Biosciences, Lowers Price Target to $10
Ventyx Biosciences Analyst Ratings
Ventyx Biosciences (VTYX) Receives a Buy From LifeSci Capital
Stifel Nicolaus Keeps Their Hold Rating on Ventyx Biosciences (VTYX)
Analysts Offer Insights on Healthcare Companies: Quantum-Si (QSI), Savara (SVRA) and Ventyx Biosciences (VTYX)
Ventyx Biosciences (VTYX) Receives a Buy From Oppenheimer
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Incyte (INCY) and Ventyx Biosciences (VTYX)
Ventyx Biosciences: A Prudent Hold Amidst Promising Drug Potential and Market Uncertainties
Buy Rating for Ventyx Biosciences Based on Clinical and Financial Strengths
Ventyx Biosciences (VTYX) Gets a Buy From LifeSci Capital
Ventyx Biosciences Analyst Ratings
Buy Rating Affirmed for Ventyx Biosciences on Strong Clinical Pipeline and Promising Drug Developments
Buy Rating Affirmed: Ventyx Biosciences' Promising Clinical Advances and Strategic Position for Market Opportunities
Ventyx Biosciences (VTYX) Receives a New Rating From Piper Sandler
Oppenheimer Upgrades Ventyx Biosciences to Outperform, Announces $12 Price Target
Maintaining Hold on Ventyx Biosciences Amidst Anticipation of NLRP3 Inhibitor Data and Financial Stability
Lifesci Capital Upgrades Ventyx Biosciences to Outperform From Market Perform, $5 Price Target
Ventyx Biosciences (VTYX) Receives a Buy From Piper Sandler
Analysts Have Conflicting Sentiments on These Healthcare Companies: Irhythm Technologies (IRTC), Ventyx Biosciences (VTYX) and Rewalk Robotics (LFWD)